University Of California, San Francisco

MTX110 shows promising PFS and OS in Phase 1 study for recurrent glioblastoma, outperforming historic norms. The CED technology delivers high drug concentrations directly to tumors, potentially reducing side effects and improving survival.

MTX110 shows promising survival outcomes in recurrent glioblastoma, with patients achieving 12-13 months OS and 6-12 months PFS, using a novel CED delivery system.

Arc Institute adds seven leading scientists to its Investigator Program and Ignite Award cohorts, focusing on complex human diseases. Applications for 2025 Investigator and Fellow programs are open.

Laura J. van ’t Veer, PhD, to receive the William L. McGuire Memorial Lecture Award at SABCS 2024 for her contributions in breast cancer research, including the development of MammaPrint and leadership in the I-SPY 2 trials.

In 2025, pulmonology advances include new COPD treatments like ensifentrine (Ohtuvayre) and dupilumab (Dupixent), the first biologic therapy for COPD. Ensifentrine, a dual inhibitor of phosphodiesterase 3 and 4, improved FEV1 and reduced exacerbations in trials. Dupilumab, approved for COPD with eosinophilic phenotype, reduced exacerbations and improved lung function in BOREAS and NOTUS trials.

Experts discuss the use of sacituzumab govitecan and trastuzumab deruxtecan in breast cancer treatment, focusing on safety profiles, supportive care, and therapeutic sequencing. They highlight the importance of G-CSF use, the modest overall survival improvement with sacituzumab, and the better tolerability of trastuzumab deruxtecan. The discussion also covers the management of treatment-related toxicities, particularly neutropenia and diarrhea, and the need for early intervention with steroids to mitigate adverse effects.

New self-adjusting neuromodulation, tested at UCSF, uses AI to personalize treatment for Parkinson’s disease by adapting to brain activity changes, marking a shift towards precision medicine in neurology.

FDA approved vorasidenib (Voranigo) for IDH-positive grade 2 astrocytoma or oligodendroglioma patients, based on INDIGO trial results. Dr. Jennie W. Taylor discussed this in an OncLive On Air podcast.

A study of 9,538 9- and 10-year-olds found higher screen time linked to increased risks for ADHD, depression, and conduct issues. Video chat, texting, videos, and video games were most associated with depressive symptoms. The effect was stronger for white adolescents than Black adolescents, who may use screens to connect with peers. The American Academy of Pediatrics recommends a Family Media Use Plan.

The gut microbiome's balance affects autoimmune diseases, with dysbiosis leading to altered immune responses. Beneficial gut bacteria produce short-chain fatty acids that aid immune cell development, while microbial metabolites and peptides can regulate immune cell activity. Imbalances in gut microbiota, such as changes in Bacteroidetes/Firmicutes ratio, contribute to diseases like rheumatoid arthritis and multiple sclerosis. Precision medicine aims to manipulate the gut microbiome to improve autoimmune therapy, though human studies are needed to better understand these complex interactions.